Dr. Reddy’s Announces the Approval of Azacitidine for Injection

  Dr. Reddy’s Announces the Approval of Azacitidine for Injection

Business Wire

HYDERABAD, India -- September 17, 2013

Dr. Reddy’s Laboratories (NYSE: RDY) announced today that Azacitidine for
Injection 100 mg/vial, a bioequivalent generic version of VIDAZA^®
(azacitidine for injection), is approved by the United States Food & Drug
Administration (USFDA) on September 16, 2013. The launchof product in the
market is planned in the near-term.

The VIDAZA^® brand had U.S. sales of approximately $378.5 Million for the most
recent twelve months ending July 2013 according to IMS Health.

Dr. Reddy’s Azacitidine for Injection 100 mg/vial is available in single-use
vials.

Disclaimer

This press release includes forward-looking statements, as defined in the U.S.
Private Securities Litigation Reform Act of 1995. We have based these
forward-looking statements on our current expectations and projections about
future events. Such statements involve known and unknown risks, uncertainties
and other factors that may cause actual results to differ materially. Such
factors include, but are not limited to, changes in local and global economic
conditions, our ability to successfully implement our strategy, the market
acceptance of and demand for our products, our growth and expansion,
technological change and our exposure to market risks. By their nature, these
expectations and projections are only estimates and could be materially
different from actual results in the future.

About Dr. Reddy's

Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global
pharmaceutical company, committed to providing affordable and innovative
medicines for healthier lives. Through its three businesses – Pharmaceutical
Services and Active Ingredients, Global Generics and Proprietary Products –
Dr. Reddy’s offers a portfolio of products and services including APIs, custom
pharmaceutical services, generics, biosimilars and differentiated
formulations. Major therapeutic focus is on gastro-intestinal, cardiovascular,
diabetology, oncology, pain management and anti-infective. Major markets
include India, USA, Russia-CIS and Europe apart from other select geographies
within Emerging Markets.

VIDAZA^® is a registered trademark of Celgene Corporation.
IMS National Sales Perspectives: Retail and Non-Retail MAT July 2013

Contact:

Dr. Reddy’s Laboratories Ltd.
Investors and Financial Analysts:
Kedar Upadhye, +91-40-66834297
kedaru@drreddys.com
or
Saunak Savla, +91-40-49002135
saunaks@drreddys.com
or
Milan Kalawadia (USA), +1 908-203-4931
mkalawadia@drreddys.com
or
Media:
S Rajan, +91-40- 49002445
rajans@drreddys.com